Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/26/2025 | $14.00 | Buy | Citigroup |
1/8/2025 | $16.00 | Buy | Truist |
12/13/2024 | $16.00 | Outperform | Wedbush |
12/10/2024 | $15.00 | Mkt Outperform | JMP Securities |
7/15/2024 | $10.00 → $15.00 | Neutral → Overweight | JP Morgan |
6/24/2024 | $12.00 | Market Perform → Outperform | Leerink Partners |
5/31/2024 | $20.00 | Overweight | Piper Sandler |
3/28/2024 | $40.00 | Outperform | William Blair |
Citigroup initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $14.00
Truist initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00
Wedbush initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $16.00
CHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation investigational gene therapy intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 26th Annual Scientific Meeting of Neuromuscular Study Group (NMSG), September 26-28, 2025, in Stresa, Italy. Presentations will include previously reported Day 90 biopsy data in addition to updated safety data as of the August 12, 2025, data cutoff from the INSPIRE DUCHENNE trial. "Our presentat
- Non-exclusive license for Solid's proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio's gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is eligible for certain development and sales milestones and tiered royalties on net sales -- Solid continues to expand collaborative efforts for AAV-SLB101 with more than 25 agreements and licenses executed to date - CHARLESTOWN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a n
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 18, 2025 /PRNewswire/ -- USA News Group News Commentary –Today, Americans over 65 command $22,356 in annual healthcare spending per person versus just $4,217 for children[1], driving unprecedented investment in longevity solutions as populations worldwide confront global demographics where those aged 60+ will surge from 900 million in 2015 to 2 billion by 2050[2]. These macro forces position Avant Technologies, Inc. (OTCQB:AVAI), HCW Biologics Inc. (NASDAQ:HCWB), Solid Biosciences Inc. (NASDAQ:SLDB), ProMIS Neuorsciences, Inc. (NASDAQ:PMN), and uniQure N.V. (NASDAQ:QURE).
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
SCHEDULE 13D/A - Solid Biosciences Inc. (0001707502) (Subject)
10-Q - Solid Biosciences Inc. (0001707502) (Filer)
8-K - Solid Biosciences Inc. (0001707502) (Filer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash and investments; Anticipated cash runway through multiple important pipeline milestones and into 2025 – CHARLESTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update. "We are pleased with the continued advanceme
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid's focus on both neuromuscular and cardiac diseases - CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer. "We are excited to welcome Dr. Brooks to Solid Biosciences during this pivotal time in our company's history, advancing towards the clinic with our next generation gene therapy for Duc
— Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia - - Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease - - Phase 1b clinical trial initiation expected in 2H 2025 - - Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET - CHARLESTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today a
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with Duchenne; Anticipated dosing in late – 2023, subject to IND clearance - - Company ends 2022 with approximately $213.7 million in cash and investments; Anticipated cash runway into 2025 - CHARLESTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financ
SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)